Bayer AG (BSE:BAYN) EBIT: lei194 Mil (TTM As of Mar. 2026)


BSE:BAYN Bayer AG BSE:BAYN
76 GF Score
Price lei209.00
GF Value lei139.16
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Bayer AG EBIT?

Bayer AG BSE:BAYN +2.05% 76 EBIT is lei194 Mil as of Mar. 2026. GuruFocus rates BSE:BAYN with a GF Score™ of 76/100 and a GF Value™ of lei139.16 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Bayer AG's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was lei18,116 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was lei194 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bayer AG's annualized ROC % for the quarter that ended in Mar. 2026 was 13.37%. Bayer AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 108.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bayer AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.05%.


Bayer AG  (BSE:BAYN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bayer AG's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=73824.488 * ( 1 - 7.43% )/( (506927.546 + 515332.808)/ 2 )
=68339.3285416/511130.177
=13.37 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=553932.4 - 45277.474 - ( 41626.663 - max(0, 172658.452 - 174385.832+41626.663))
=506927.546

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=564690.38 - 39726.699 - ( 34840.639 - max(0, 175040.207 - 184671.08+34840.639))
=515332.808

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bayer AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=72464.344/( ( (67023.378 + max(-18582.574, 0)) + (66579.101 + max(-36530.358, 0)) )/ 2 )
=72464.344/( ( 67023.378 + 66579.101 )/ 2 )
=72464.344/66801.2395
=108.48 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(48096.387 + 65359.583 + 15996.804) - (45277.474 + 0 + 102757.874)
=-18582.574

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(67520.74 + 62849.165 + 8139.944) - (39726.699 + 0 + 135313.508)
=-36530.358

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bayer AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=193.748/355068.868
=0.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bayer AG EBIT Related Terms


Bayer AG EBIT Historical Data

* Premium members only.

The historical data trend for Bayer AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG EBIT Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17,348.77 31,287.41 2,102.17 113.72 -4,578.09

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,266.27 -187.89 -2,119.15 -15,615.30 18,116.09

BSE:BAYN vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bayer AG's EV-to-EBIT falls into.


BSE:BAYN
76GF Score
Bayer AG BSE:BAYN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei194 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of lei194 Mil mean?
Bayer AG (BSE:BAYN) has a EBIT of lei194 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bayer AG.
Is Bayer AG's EBIT too high?
Bayer AG's current EBIT is lei194 Mil. Overall, Bayer AG has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EBIT compare to LLY and JNJ?
Bayer AG's EBIT of lei194 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bayer AG. Bayer AG's current EBIT is lei194 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (BSE:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is lei139.16, compared to a current price of lei209.00 — trading 50.2% above its estimated fair value. The current EBIT is lei194 Mil. Bayer AG's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bayer AG (BSE:BAYN), the current EBIT is lei194 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (BSE:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of lei209.00 is trading 50.2% above its estimated GF Value™ of lei139.16. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for BSE:BAYN:

  • EBIT: lei194 Mil
  • GF Value™: lei139.16 vs. price of lei209.00 (50.2% above fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the BSE:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
76GF Score

Get the complete analysis for BSE:BAYN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei209.00
Price
lei139.16
GF Value